Synovial sarcoma of peripheral nerve (SSPN) is rare with only 26 cases reported in English. SSPN is often mistaken for a benign or malignant peripheral nerve sheath tumor (PNST) by clinicians and pathologists. Fifteen cases of SSPN were retrieved from the pathology files of 3 institutions. All tumors arose in a nerve based on imaging and/or operative findings and the diagnoses were histologically confirmed. Neuropathic symptoms predominated in 11 women and 4 men, 19- to 62-year-old (median, 39 years) with tumors involving the ulnar (5), median (3), peroneal (3) or sciatic (2) nerve, or the L4 or T1 nerve root (2). Tumor sizes ranged from 2 to 13 cm (median, 3.8 cm). The leading clinical diagnosis was PNST (9). Treatment was surgical (14) supplemented with radiation therapy (8) and chemotherapy (6). Fourteen tumors were monophasic and 1 was biphasic; 4 had poorly differentiated (PD) foci (1 rhabdoid). Diagnoses in 12 cases were verified by fluorescence in situ hybridization, reverse transcription polymerase chain reaction or both methods. Follow-up in 14 patients (median, 32 mo) revealed that 2/4 patients with PD tumors died with pulmonary metastases; another was alive with no current evidence of disease (NED) following 2 local recurrences, while the fourth had NED. In contrast, 9/10 patients without PD tumors were alive (7 NED) and 1 died at 12 months with pulmonary infiltrates. SSPN is under-recognized clinically and histologically as it mimics benign and malignant PNST. Molecular analysis is recommended to confirm the diagnosis. PD foci, including rhabdoid areas, may portend a worse outcome, similar to non-neural-based tumors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/PAS.0000000000000874 | DOI Listing |
BMJ Case Rep
January 2025
Department of Orthopaedic Surgery, Pontificia Universidad Catolica de Chile, Santiago, RM, Chile
The hindfoot is an uncommon site for malignant tumours. While limb salvage procedures are now more common for treating bone sarcoma, there is limited information available on hindfoot reconstruction alternatives because of its low incidence and its challenging outcomes. We present a case report of a man in his late 60s with synovial sarcoma affecting the right heel (calcaneus and soft tissue).
View Article and Find Full Text PDFJBJS Case Connect
January 2025
Department of Surgery, Plastic and Reconstructive Surgical Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Case: Wide resection of a synovial sarcoma of the anteromedial distal leg involving the dimetaphyseal tibia and posterior tibial tendon produced an 8.5-cm osseous defect. To keep the free flap from invaginating into the defect and prevent kinking of the anastomosis, six 1.
View Article and Find Full Text PDFAnticancer Agents Med Chem
January 2025
Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Henan Zhengzhou, 450052, China.
Background: Anlotinib has demonstrated durable clinical benefits in patients with unresectable or metastatic bone and soft-tissue sarcomas.
Methods: 92 patients treated with chemotherapy combined with or without anlotinib were collected and analyzed. The objective response rate (ORR) and disease control rate (DCR) were analyzed.
Radiol Case Rep
March 2025
Department of Radiology, Columbia University College of Physicians and Surgeons, Harlem Hospital Center, New York, NY, USA.
Synovial sarcoma is a common but aggressive subset of sarcomatous tumors that often arises adjacent to the large joints of extremities. We present a case of a 33-year-old male with no medical history and an initial complaint of right leg pain. On further radiological and pathological investigation, he was diagnosed with synovial sarcoma in the medial soft tissues of his thigh.
View Article and Find Full Text PDFActa Oncol
January 2025
Comprehensive Cancer Center Munich and Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; Bavarian Cancer Research Center (BZKF), Munich, Germany.
Background: The prognosis of patients with advanced soft tissue sarcoma (STS) remains dismal. Trofosfamide (TRO) has been proposed as a well-tolerated oral maintenance therapy. This retrospective analysis aims to determine the value of this therapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!